1-3 of 3
Edith Szafer-Glusman
Close
Sort by
Journal Articles

Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study

Clinical Trials & Observations
Carol Moreno, Isabelle G. Solman, Constantine S. Tam, Andrew Grigg, Lydia Scarfò, Thomas J. Kipps, Srimathi Srinivasan, Raghuveer Singh Mali, Cathy Zhou, James P. Dean, Edith Szafer-Glusman, Michael Choi
Journal: Blood Advances
Blood Adv (2023) 7 (18): 5294–5303.
https://doi.org/10.1182/bloodadvances.2023010236
Published: 2023
Includes: Supplemental data
Journal Articles

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting

Maissa Mhibik, Erika M. Gaglione, David Eik, John Herrick, Janet Le, Inhye E. Ahn, Christopher Chiu, Monica Wielgos-Bonvallet, Ida H. Hiemstra, Esther C. W. Breij, Jenny Chen, Edward B. Reilly, Pearlie K. Epling-Burnette, Edith Szafer-Glusman, Clare Sun, Adrian Wiestner
Journal: Blood Advances
Blood Adv (2023) 7 (15): 4089–4101.
https://doi.org/10.1182/bloodadvances.2022009517
Published: 2023
Includes: Supplemental data
Journal Articles

Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets

Christopher R. Bolen, Ronald McCord, Sarah Huet, Garrett M. Frampton, Richard Bourgon, Fabrice Jardin, Peggy Dartigues, Elizabeth A. Punnoose, Edith Szafer-Glusman, Luc Xerri, Pierre Sujobert, Gilles Salles, Jeffrey M. Venstrom
Journal: Blood Advances
Blood Adv (2017) 1 (22): 1884–1890.
https://doi.org/10.1182/bloodadvances.2016000786
Published: 2017
Includes: Supplemental data